• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Repaglinide Teva
    / Teva

    Active Ingredient
    Repaglinide 0.5, 1, 2 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    90 X 0.5 mg

    partial basket chart 84066 18419


    90 X 1 mg

    partial basket chart 84067 18420


    90 X 2 mg

    partial basket chart 84068 18421

    Related information


    The usual starting dose is 0.5 mg before each main meal.
    Swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal.
    Your doctor will adjust your dose, up to 4 mg, to be taken immediately before or up to 30 minutes before each main meal.
    The maximum recommended daily dose is 16 mg.
    See prescribing information for full details.


    Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) in patients whose hyperglycemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
    Also indicated in combination with metformin in Type 2 diabetes patients who are not satisfactorily controlled on metformin alone.
    Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.


    Known hypersensitivity to the active ingredient, or to any other ingredient of the preparation.
    Type 1 diabetes (Insulin-Dependent Diabetes Mellitus: IDDM), C-peptide negative.
    Diabetic ketoacidosis, with or without coma.
    Pregnancy and lactation.
    Severe hepatic function disorder.
    Concomitant use with gemfibrozil (concomitant use may prolong the effects of repaglinide).

    Teva Pharmaceutical Industries Ltd, Israel